This article is more than 5 years old. Information may no longer be current.
Bausch + Lomb acquires assets, U.S. rights to topical treatment for herpetic keratitis
Click Here to Manage Email Alerts
ROCHESTER, N.Y. — Bausch + Lomb has acquired the assets and U.S. rights for Zirgan from Sirion Therapeutics, Bausch + Lomb announced in a press release.
Approved by the U.S. Food and Drug Administration in 2009 for treating acute herpetic keratitis, Zirgan (ganciclovir ophthalmic gel 0.15%) has been the standard treatment for corneal ulcers in Europe for more than a decade under the brand name Virgan, according to the release.
"Our acquisition of Zirgan reflects our strategy to bring innovative products to the ophthalmic community," Philip Gioia, head of North America Pharmaceuticals for Bausch + Lomb, said in the release. "With its tolerability, convenience and targeted anti-viral effect, we believe Zirgan will experience rapid adoption by U.S. physicians for the benefit of their patients."
Zirgan is currently available by prescription at U.S. pharmacies and is stocked with all major U.S. pharmaceutical wholesalers.
Financial terms of the acquisition were not disclosed.
Follow OSNSuperSite.com
on Twitter.